Cancer drug and uses
A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.
1. A method of treating a cancer, the method comprising administering one or more cancer therapeutics to an individual with the cancer, wherein the one or more cancer therapeutics include
a) a first cancer therapeutic that is a therapeutically effective does of an anti-diabetic drug;
b) a second cancer therapeutic that is a therapeutically effective dose of a statin; and
c) a third cancer therapeutic that is a therapeutically effective dose of a glycolysis inhibitor.
2. The method according to claim 1 , wherein the anti-diabetic drug is a biguanide, a thiazolidinedione, a secretagogue, an alpha-glucosidase inhibitor and/or a peptide analog, a cinnamon, a thiamine or any combination thereof.
3. The method according to claim 2 , wherein the biguanide is a metformin, a phenformin and/or a buformin.
4. The method according to claim 1 , wherein the statin is an atorvastatin, a fluvastin, a lovastatin, a pitavastatin, a pravastatin, a rosuvastatin, a simvastatin or any combination thereof.
5. The method according to claim 1 , wherein the glycolysis inhibitor includes a hexokinase inhibitor, a phosphoglucose isomerase inhibitor, a fructosebisphosphate inhibitor, a triosephosphate isomerase inhibitor, a glyceraldehyde phosphate dehydrogenase inhibitor, a phosphoglycerate kinase inhibitor, a phosphoglycerate mutase inhibitor, an enolase inhibitor and/or a pyruvate kinase inhibitor, an anti-helminthic agent, an anti-malarial agent, an antibiotic or any combination thereof.
6. The method according to claim 5 , wherein the anti-helminthic agent includes an abamectin, an aminoacetonitriles, a benzimidazole, a diethylcarbamazine, an ivermectin, a levamisole, niclosamide, an octadepsipeptides, a phosphoric acid, a praziquantel, a spiroindoles, a suramin, a pyrantel pamoate or any combination thereof.
7. The method according to claim 6 , wherein the benzimidazole is an albendazole, a fenbendazole, a flubendazole, a thiabendazole or a triclabendazole.
8. The method according to claim 7 , wherein the flubendazole is a mebendazole.
9. The method according to claim 5 , wherein the anti-malarial agent includes an amodiaquine, an artemisinin, an atovaquone, a chloroquine, a clindamycin, a doxycycline, a halofantrine, a mefloquine, a primaquine, a proguanil, a pyrimethamine, a quinine, a rufigallol, a sulphonamide or any combination thereof.
10. The method according to claim 9 , wherein the artemisinin is an arteether, an artelinate, an artelinic acid, an artemether, an artemotil, an artemisinin, an artenimol, an arterolane, an artesunate, a dihydroartemisinin and/or a dihydroartemisinin methyl ether.
11. The method according to claim 5 , wherein the therapeutically effective dose of the anti-diabetic drug is in an amount of 1 mg/kg/day to about 40 mg/kg/day, the therapeutically effective dose of the statin is in an amount of 0.01 mg/kg/day to about 10 mg/kg/day, the therapeutically effective dose of the anti-helminthic agent is in an amount of 0.01 mg/kg/day to about 10 mg/kg/day and the therapeutically effective dose of the anti-malarial agent is in an amount of 0.01 mg/kg/day to about 10 mg/kg/day.
12. The method according to claim 5 , wherein the one or more cancer therapeutics comprise an anti-diabetic drug, a statin, an anti-helminthic agent and an anti-malaria agent.
13. The method according to claim 1 , further comprising administering a fourth cancer therapeutic that is a therapeutically effective dose of a therapeutic that is a glucose intake inhibitor.
14. The method according to claim 13 , wherein the glucose intake inhibitor includes a GLUT-1 receptor inhibitor.
15. The method according to claim 14 , wherein the GLUT-1 receptor inhibitor is Vitamin C.
16. The method according to claim 1 , further comprising administering a fourth cancer therapeutic that is a therapeutically effective dose of a therapeutic that is a lipid intake inhibitor.
17. The method according to claim 16 , wherein the lipid intake inhibitor includes an LDL receptor inhibitor, an SR-81 inhibitor, an SR-82 inhibitor, a SR-83/CD36receptor inhibitor or any combination thereof.
18. The method according to claim 17 , wherein the LDL receptor inhibitor is Vitamin D.
19. The method according to claim 1 , wherein the one or more cancer therapeutics comprise metformin, atorvastatin, mebendazole and doxycycline.
20. The method according to claim 1 , done in conjunction with a chemotherapy, a radiation therapy, a surgery, an immunotherapy, or a freezing a tumor.
21. The method according to claim 1 , wherein the cancer is a brain cancer, a bladder cancer, a breast cancer, a colon cancer, a rectal cancer, an endometrial cancer, a kidney cancer, a renal cancer, a leukemia, a lung cancer, a melanoma, a non-Hodgkins lymphoma, a pancreatic cancer, a prostate cancer, a stomach cancer or a thyroid cancer.
22. The method according to claim 1 , wherein the one or more cancer therapeutics comprise an anti-diabetic drug, a statin, an anti-helminthic agent and an anti-malaria agent.
23. The method according to claim 1 , wherein the one or more cancer therapeutics comprise a biguanide, a statin, a benzimidazole and a doxycycline.